PPCB Propanc Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1517681 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY64.3%
TTM EPS YoY115.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-211.0%
ROA-159.8%
ROIC (approx.)-168.8%
Asset turnover—
Leverage & solvency
Liabilities / assets31.5%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-154.29x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-119.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $457,677 | $375,655 | $169,660 | $19,961 | $60,201 | $53,522 | $54,097 | $54,388 |
| SG&A expense | $182,728 | -$13.78M | $6.22M | $3.63M | $137,341 | $3.59M | $53.07M | $153,593 |
| Operating income | -$8.57M | -$3.46M | -$6.40M | -$3.65M | -$4.67M | -$3.65M | -$53.13M | -$213,382 |
| Interest expense | $18,244 | $27,665 | $38,270 | $58,955 | $305,649 | $254,542 | $104,042 | $118,943 |
| Pretax income | -$8.59M | -$4.57M | -$6.36M | -$3.09M | -$4.84M | -$4.07M | -$54.07M | -$430,183 |
| Net income | -$8.59M | -$4.57M | -$6.36M | -$3.09M | -$4.84M | -$4.07M | -$54.07M | -$430,183 |
| EBITDA | -$8.57M | -$3.46M | -$6.40M | -$3.65M | -$4.67M | — | -$53.13M | — |
| EPS (basic) | -12.22 | — | -0.28 | -0.30 | -98.08 | — | -12.50 | -32.23 |
| EPS (diluted) | -12.22 | — | -0.28 | -0.30 | -98.08 | — | -12.50 | -32.23 |
| Weighted avg. shares (diluted) | 702,966 | — | 22.43M | 13.36M | 49,326 | — | 4.33M | 13,347 |
| Balance sheet | ||||||||
| Cash & equivalents | $258,366 | $832,006 | $443,702 | $561,237 | $602,737 | $12,088 | $50,760 | $14,633 |
| Current assets | $8.00M | $8.54M | $8.22M | $7.71M | $8.76M | $8.35M | $9.74M | $17,984 |
| PP&E, net | $4,030 | $3,915 | $4,221 | $4,397 | $2,364 | — | — | — |
| Total assets | $10.33M | $12.78M | $14.33M | $15.11M | $17.98M | $19.63M | $22.53M | $78,533 |
| Current liabilities | $3.24M | $3.35M | $3.48M | $3.62M | $3.57M | $5.58M | $4.34M | $4.15M |
| Long-term debt | — | — | $55,000 | $55,000 | $106,968 | $537,921 | $438,578 | $409,799 |
| Total debt | — | — | $55,000 | $55,000 | $106,968 | $537,921 | $438,578 | $409,799 |
| Total liabilities | $3.26M | $3.38M | $3.51M | $3.66M | $3.61M | $5.73M | $4.44M | $4.24M |
| Shareholders' equity | $7.07M | $9.40M | $9.83M | $10.45M | $14.36M | $13.91M | $18.09M | -$4.16M |
| Net debt | — | — | -$388,702 | -$506,237 | -$495,769 | $525,833 | $387,818 | $395,166 |
| Shares outstanding | 983,260 | 331,083 | 21.86M | 13.45M | 12.81M | 464,471 | 11.61M | 14,508 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.97M | -$1.60M | -$1.14M | -$999,140 | -$1.94M | -$27,186 | -$96,196 | -$6,271 |
| Capital expenditure | — | $21 | $154 | $2,267 | $2,491 | — | — | — |
| Free cash flow | — | -$1.60M | -$1.14M | -$1.00M | -$1.94M | — | — | — |
| Investing cash flow | — | -$21 | -$154 | -$2,267 | -$2,491 | — | — | — |
| Financing cash flow | $1.40M | $1.98M | $981,614 | $965,099 | $2.53M | $7,756 | $147,485 | $79,816 |
| Depreciation & amortization | $354 | $327 | $316 | $229 | $125 | — | $0 | — |
| Stock-based compensation | $1.93M | $1.23M | $5.35M | $1.79M | $3.02M | $3.12M | $52.84M | — |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.